DDInter125 DDInter1660
Developed by Schering-Plough after its merger with Organon International, asenapine is a sublingually administered, atypical antipsychotic for treatment of schizophrenia and acute mania associated with bipolar disorder. Asenapine also belongs to the dibenzo-oxepino pyrrole class. It is also for severe post-traumatic stress disorder nightmares in soldiers as an off-label use. FDA approved on August 13, 2009.
Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. Semaglutide was developed by Novo Nordisk and approved by the FDA for subcutaneous injection in December 2017. The tablet formulation was approved for oral administration in September 2019. Semaglutide works by binding to and activating the GLP-1 receptor, thereby stimulating insulin secretion and reducing blood glucose. The subcutaneous injection is administered once weekly and the tablet is administered once a day. Semaglutide offers a competitive advantage over other drugs used to manage diabetes, which may require several daily doses. Clinical trials have determined that this drug reduces glycosylated hemoglobin (HbA1c) levels and reduces body weight, proving to be effective for patients with type 2 diabetes. In June 2021, semaglutide was approved by the FDA for chronic weight management in adults with general obesity or overweight who have at least one weight-related condition, marking semaglutide as the first approved drug for such use since 2014. The use of semaglutide in weight management is also approved by Health Canada and the EMA. On May 31, 2023, the FDA issued a warning regarding the use of compounded semaglutide after receiving adverse event reports. The use of salt forms of semaglutide, including semaglutide sodium and semaglutide acetate, has not been proven to be safe or effective.
Asenapine {u} (Compound) resembles {v} (Compound) Loxapine
Loxapine {u} (Compound) resembles {v} (Compound) Clozapine
Clozapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Asenapine {u} (Compound) resembles {v} (Compound) Loxapine
Loxapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Promethazine
Promethazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Asenapine {u} (Compound) binds {v} (Gene) HRH2
HRH2 {u} (Gene) is bound by {v} (Compound) Olanzapine
Olanzapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Asenapine {u} (Compound) resembles {v} (Compound) Amoxapine
Amoxapine {u} may lead to a major life threatening interaction when taken with {v} Pasireotide
Pasireotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Asenapine {u} (Compound) resembles {v} (Compound) Loxapine
Loxapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Thiethylperazine
Thiethylperazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Asenapine {u} (Compound) resembles {v} (Compound) Loxapine
Loxapine {u} (Compound) resembles {v} (Compound) Trifluoperazine
Trifluoperazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Asenapine {u} (Compound) resembles {v} (Compound) Amoxapine
Amoxapine {u} may lead to a major life threatening interaction when taken with {v} Phenylephrine
Phenylephrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Asenapine {u} (Compound) binds {v} (Gene) ADRB2
ADRB2 {u} (Gene) is upregulated by {v} (Compound) Thioridazine
Thioridazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Asenapine {u} (Compound) downregulates {v} (Gene) IGFBP2
IGFBP2 {u} (Gene) is downregulated by {v} (Compound) Estradiol
Estradiol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Asenapine {u} (Compound) causes {v} (Side Effect) Parkinsonism
Parkinsonism {u} (Side Effect) is caused by {v} (Compound) Lurasidone
Lurasidone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Asenapine (Compound) resembles Loxapine (Compound) and Loxapine (Compound) resembles Clozapine (Compound) and Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Asenapine (Compound) resembles Loxapine (Compound) and Loxapine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Asenapine (Compound) binds HRH2 (Gene) and HRH2 (Gene) is bound by Olanzapine (Compound) and Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Asenapine (Compound) resembles Amoxapine (Compound) and Amoxapine may lead to a major life threatening interaction when taken with Pasireotide and Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Asenapine (Compound) resembles Loxapine (Compound) and Loxapine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Asenapine (Compound) resembles Loxapine (Compound) and Loxapine (Compound) resembles Trifluoperazine (Compound) and Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Asenapine (Compound) resembles Amoxapine (Compound) and Amoxapine may lead to a major life threatening interaction when taken with Phenylephrine and Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Asenapine (Compound) binds ADRB2 (Gene) and ADRB2 (Gene) is upregulated by Thioridazine (Compound) and Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Asenapine (Compound) downregulates IGFBP2 (Gene) and IGFBP2 (Gene) is downregulated by Estradiol (Compound) and Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Asenapine (Compound) causes Parkinsonism (Side Effect) and Parkinsonism (Side Effect) is caused by Lurasidone (Compound) and Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide